JUPITER Trial
New England Journal of Medicine (2008)
44% MACE reduction in 17,802 patients with LDL <130 but hsCRP ≥2.
Rosuvastatin
Oral tablet (5mg, 10mg, 20mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
RosuvastatinRosuvastatin
High-intensity statin with the greatest LDL-lowering potency (40 to 55%). Hydrophilicity reduces muscle/CNS penetration. JUPITER trial showed primary prevention benefit even with normal LDL but elevated hsCRP.
LDL-C reduction 45 to 55%
JUPITER: 44% MACE reduction in primary prevention
hsCRP reduction ~37%
Plaque regression (ASTEROID trial)
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Competitively inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptors. Pleiotropic anti-inflammatory effects include hsCRP reduction and endothelial function improvement.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Rosuvastatin.
ASTEROID Trial
JAMA (2006)
40mg produced significant atherosclerotic plaque regression by IVUS at mean LDL 60.8 mg/dL.
Safety profile
Monitoring & safety information.
Commonly reported side effects
- Myalgia (5 to 10%)
- Headache
- GI disturbance
- Elevated transaminases
- New-onset diabetes (class effect)
Less common but serious risks
- Myopathy/rhabdomyolysis (rare)
- Statin-associated autoimmune myopathy (very rare)
- New-onset T2DM (~10 to 12% relative risk increase)
- Asian patients: higher plasma levels, start at 5mg
Generally not appropriate for
- Active liver disease
- Pregnancy
- Concurrent cyclosporine
- Asian patients: max 20mg
Typical monitoring
- Lipid panel (LDL-C, ApoB, Lp(a))
- Liver function (baseline)
- CK if myalgia
- Fasting glucose/HbA1c annually
FAQ
Quick answers.
High-intensity statin with the greatest LDL-lowering potency (40 to 55%). Hydrophilicity reduces muscle/CNS penetration. JUPITER trial showed primary prevention benefit even with normal LDL but elevated hsCRP.
LDL-C reduction 45 to 55%. JUPITER: 44% MACE reduction in primary prevention. hsCRP reduction ~37%. Plaque regression (ASTEROID trial). Hydrophilic, less muscle/CNS side effects.
Common side effects include: myalgia (5 to 10%), headache, gi disturbance, elevated transaminases, new-onset diabetes (class effect). Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
High-intensity statin with the greatest LDL-lowering potency (40 to 55%). Hydrophilicity reduces muscle/CNS penetration. JUPITER trial showed primary prevention benefit even with normal LDL but elevated hsCRP.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.